Changing Trade Rules in India Could Impede Access to Generic Drugs
September 15, 2010
Generic drugs produced in India "could cost more and be harder to access if the country has to adhere to stricter intellectual property rules," Reuters reports, noting that the country supplies the "bulk" of AIDS medicines that go developing countries. The article cites a new Journal of the International AIDS Society study, written by a UNITAID official and other experts, that said Indian trade deals have "have already begun to complicate efforts to get cheap, life-saving drugs to poorer countries." The study authors also said trade talks between India and the EU could result in extended patent terms, data exclusivity and border enforcement, which could increase the price of antiretrovirals (ARVs), limit dosage options and delay access (MacInnis, 9/14).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)